aTYR PHARMA (ATYR) Restructuring Costs (2024 - 2026)

aTYR PHARMA (ATYR) has reported Restructuring Costs for 3 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Restructuring Costs fell 17.72% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $13.0 million (up 2.58% YoY), and the FY2025 full-year result was $13.7 million, up 20.42% from the prior year.
• Restructuring Costs climbed to $3.2 million in Q2 2026 per ATYR's latest filing, from $3.1 million in the prior quarter.
• Across five years, Restructuring Costs topped out at $3.9 million in Q2 2025 and bottomed at $2.8 million in Q2 2024.
• Historically, Restructuring Costs has averaged $3.1 million across 3 years, with a median of $3.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Restructuring Costs surged 42.32% in 2025, then slipped 17.72% in 2026.
• Over 3 years, Restructuring Costs stood at $2.9 million in 2024, then declined by 2.6% to $2.8 million in 2025, then increased by 13.4% to $3.2 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $3.2 million, $3.1 million, and $2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.